Sarepta Therapeutics Inc (NASDAQ:SRPT) Shares Bought by Great West Life Assurance Co. Can

Great West Life Assurance Co. Can increased its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 14.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,574 shares of the biotechnology company’s stock after buying an additional 1,098 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Sarepta Therapeutics were worth $1,018,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of SRPT. Northern Trust Corp grew its stake in Sarepta Therapeutics by 6.5% in the fourth quarter. Northern Trust Corp now owns 318,287 shares of the biotechnology company’s stock valued at $34,734,000 after purchasing an additional 19,473 shares in the last quarter. Columbus Circle Investors grew its stake in Sarepta Therapeutics by 57.7% in the first quarter. Columbus Circle Investors now owns 392,243 shares of the biotechnology company’s stock valued at $46,751,000 after purchasing an additional 143,552 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in Sarepta Therapeutics by 1,939.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 7,282 shares of the biotechnology company’s stock valued at $795,000 after purchasing an additional 6,925 shares in the last quarter. Piedmont Investment Advisors Inc. grew its stake in Sarepta Therapeutics by 6.2% in the fourth quarter. Piedmont Investment Advisors Inc. now owns 4,821 shares of the biotechnology company’s stock valued at $526,000 after purchasing an additional 280 shares in the last quarter. Finally, Stanley Laman Group Ltd. purchased a new position in Sarepta Therapeutics in the fourth quarter valued at about $231,000.

In related news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the business’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director now owns 21,717 shares of the company’s stock, valued at approximately $2,606,040. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is currently owned by insiders.

NASDAQ SRPT opened at $123.21 on Friday. Sarepta Therapeutics Inc has a twelve month low of $94.66 and a twelve month high of $176.50. The company has a quick ratio of 11.15, a current ratio of 12.17 and a debt-to-equity ratio of 0.35. The stock has a market cap of $8.90 billion, a P/E ratio of -22.57 and a beta of 1.96.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative return on equity of 36.26% and a negative net margin of 124.66%. The business had revenue of $87.01 million during the quarter, compared to analysts’ expectations of $86.92 million. As a group, analysts expect that Sarepta Therapeutics Inc will post -4.33 EPS for the current year.

SRPT has been the topic of a number of recent research reports. Cowen restated a “buy” rating and issued a $213.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, March 31st. Nomura boosted their price target on Sarepta Therapeutics from $205.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, February 28th. JMP Securities reaffirmed a “buy” rating and issued a $270.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, February 27th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, February 22nd. Finally, Citigroup boosted their price target on Sarepta Therapeutics from $188.00 to $201.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. One research analyst has rated the stock with a hold rating, twenty-six have given a buy rating and one has issued a strong buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and an average price target of $199.35.

ILLEGAL ACTIVITY WARNING: “Sarepta Therapeutics Inc (NASDAQ:SRPT) Shares Bought by Great West Life Assurance Co. Can” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2019/06/14/sarepta-therapeutics-inc-nasdaqsrpt-shares-bought-by-great-west-life-assurance-co-can.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: Intrinsic Value

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.